CMPS catalyst calendar

COMPASS Pathways plc

Upcoming catalysts
2
Cash runway
27.1 months
Cash & investments
$433M
Phase 3 programs
3

COMPASS Pathways plc is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on October 28, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

Cash runway is approximately 27.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 6 concluded trials, 100% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 28, 2026 est. Next quarterly earnings (projected) Earnings —
November 15, 2028 Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder Trial Milestone Phase 2/Phase 3

Track CMPS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open CMPS in the tracker

Recent history

DateEventTypePhase
August 5, 2026 Quarterly results filed (8-K) Earnings —
July 7, 2026 8-K filed: Reg FD disclosure, Other event Filing —
May 13, 2026 Quarterly results filed (8-K) Earnings —
March 24, 2026 Quarterly results filed (8-K) Earnings —
February 19, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
February 17, 2026 8-K filed: Reg FD disclosure, Other event Filing —
January 7, 2026 8-K filed: Material agreement Corporate —
November 13, 2025 Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD Trial Milestone Phase 3
November 4, 2025 Quarterly results filed (8-K) Earnings —
October 29, 2025 8-K filed: Leadership change Corporate —
September 15, 2025 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder Trial Milestone Phase 2
July 31, 2025 Quarterly results filed (8-K) Earnings —
July 29, 2025 8-K filed: Leadership change Corporate —
June 23, 2025 8-K filed: Other event Filing —
May 28, 2025 Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD Trial Milestone Phase 3
May 8, 2025 Quarterly results filed (8-K) Earnings —
April 16, 2025 8-K filed: Leadership change Corporate —
November 18, 2024 Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study Trial Milestone Phase 2
February 12, 2024 The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder Trial Milestone Phase 2
October 14, 2021 The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression Trial Milestone Phase 2
July 30, 2021 The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.